Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an announcement.
Eupraxia Pharmaceuticals announced a CFO succession as Bruce Cousins retires and Alex Rothwell takes over the role effective immediately, as of February 18, 2025. Rothwell, who previously served as Eupraxia’s CFO, brings extensive experience from Canadian capital markets and will contribute to advancing the company’s programs in EP-104GI and EP-104IAR. This transition is seen as a strategic move for Eupraxia, strengthening its leadership as it develops its pipeline of treatments for conditions like Eosinophilic Esophagitis and knee osteoarthritis, with promising market opportunities.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focusing on developing locally delivered, extended-release products to address therapeutic areas with high unmet medical needs. The company utilizes its proprietary DiffuSphere™ technology for targeted drug delivery, aiming to improve the safety, efficacy, and duration of effects of treatments in areas such as pain, inflammatory gastrointestinal diseases, oncology, and infectious diseases.
YTD Price Performance: 1.57%
Average Trading Volume: 19,998
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$163.9M
Learn more about EPRX stock on TipRanks’ Stock Analysis page.